MedTrace Logo

Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)

NCT00212004 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2018-05-23

No results posted yet for this study

Summary

To evaluate whether the pioglitazone could reduce the recurrence of myocardial infarction (MI) in patients with DM and old myocardial infarction

Conditions

Interventions

DRUG

pioglitazone

OTHER

control

Sponsors & Collaborators

  • Japan Heart Foundation

    collaborator OTHER

  • National Cerebral and Cardiovascular Center, Japan

    lead OTHER

Principal Investigators

  • Masafumi Kitakaze, MD, PhD · National Cerebral and Cardiovascular Center, Japan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2017-04-30
Completion
2018-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212004 on ClinicalTrials.gov